AB Science reports survival data for ALS drug masitinib

AB Science reported a preprint analysis from its AB10015 study showing a 5-year survival rate of 42.3% for ALS patients treated with masitinib 4.5 mg/kg/day, versus historical benchmarks of 7% to 27.8%. In patients without complete loss of functionality at baseline, the 5-year survival rate reached 52.9%, and the median overall survival for long-term survivors was 121 months versus 42 months predicted by ENCALS. The data are encouraging but remain preliminary, as they come from a preprint and the company is still running the larger placebo-controlled AB23005 trial.

Analysis

This is less a fresh fundamental catalyst for EQH than a cleaner read-through on capital appreciation from the block of AUM it stands to inherit. The market will likely underwrite a fee-rate mix that is lower than AllianceBernstein’s legacy average, so the first-order uplift is earnings, but the second-order effect is multiple expansion if the transaction meaningfully de-risks EQH’s revenue base and improves flow visibility. In other words, the important variable is not the nominal AUM transfer, but whether management can prove the incremental assets are sticky enough to re-rate the stock as a more diversified asset manager rather than a life/retirement hybrid.

The near-term risk is that investors overestimate the economic value of the added AUM before the integration path is fully visible. If the transferred assets carry below-average fee rates or are indexed/passive-heavy, the headline AUM benefit can disappoint on revenue per share, especially if existing outflows persist elsewhere in the franchise. That makes the next 1-2 quarters more about disclosure quality and mix than about the absolute size of the transaction.

EVR is the cleaner expression of analyst confidence, but the setup looks more tactical than structural: advisory sentiment tends to front-run realized fees by several months, and the stock can de-rate quickly if market activity normalizes from recent elevated levels. The contrarian read is that the market may already be pricing a benign M&A backdrop, so upside may be capped unless the pipeline broadens beyond a single headline transaction. For pair trades, EQH is the idiosyncratic beneficiary; EVR is more of a beta-to-capital-markets activity trade than a clean event winner.

Key Decisions for Investors

• Go long EQH for 3-6 months ahead of integration milestones; target a 10-15% rerating if management confirms strong retention and stable fee economics, with a stop if post-close disclosures show muted revenue contribution.
• Consider a relative-value long EQH / short a diversified financials ETF for the next earnings cycle to isolate the transaction-driven rerating versus broader sector beta.
• Buy EVR on pullbacks only, using a 1-2 quarter horizon; upside is tied to sustained M&A and ECM activity, but trim if advisory volumes normalize and the stock trades above its forward fee-growth support.
• Avoid chasing EQH on the announcement alone; wait for the first post-close AUM/margin commentary as the best entry point, since the main risk is fee-rate dilution rather than AUM loss.
• If using options, favor EQH call spreads over outright stock for the next 2 earnings prints to monetize rerating while limiting downside from integration/flow disappointment.